The company will use the funding to advance clinical trials for Tune-401, the epigenetic silencing drug for treating chronic ...

The Durham ID building in downtown Durham, NC holds the North Carolina office of Tune Therapeutics, a growing biotech startup moving into trials. Brian Gordon Launched from a Duke University lab ...

Tune Therapeutics, an epigenome-editing company with origins ... The staff is about evenly split between its Durham and Seattle sites, with a few working remotely elsewhere in the country. Investors ...

Tune Therapeutics, an epigenome-editing company based in Durham and Seattle, will be the first to initiate a human clinical trial for an epigenetic therapy for a common infectious disease. The company ...

Major investors are betting that a Durham company has a potential cure for hepatitis B. STORY HIGHLIGHTS Tune Therapeutics raised $175 million for disease treatment development. The funding ...

Tune Therapeutics, a biotech company with headquarters in Seattle and Durham, N.C., raised $175 million in one of the largest funding rounds for a Seattle-area startup in recent years. Tune ...

(Tune Photos) Tune Therapeutics, a biotech company with headquarters in Seattle and Durham, N.C., raised $175 million in one of the largest funding rounds for a Seattle-area startup in recent years.

Launched from a Duke University lab four years ago, the biotech startup Tune Therapeutics announced ... offices in Seattle and at the downtown Durham ID building. Series A and B are the two ...

Launched from a Duke University lab four years ago, the biotech startup Tune Therapeutics announced ... offices in Seattle and at the downtown Durham ID building. Series A and B are the two ...

It’s a kind of control that no one has ever tried before in patients,” Tune’s chief scientific officer said Monday.